This is a routine executive appointment with no immediate financial read-through. Monitor for upcoming clinical data readouts or pipeline updates that may be influenced by Dr. Patni's leadership.
SEPN drugs
SEPN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 25 $41.30entry
- T+1 · 3mo ago −2.54%α −2.56% · $40.25
- T+5 · 3mo ago −8.77%α −8.23% · $37.68
- T+20 · 8w ago −6.90%α −7.88% · $38.45
- T+58 · todayOpen
- T+60 · tomorrow Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Septerna appointed Rajiv Patni, M.D., as Chief Medical Officer, effective August 24, 2026. Dr. Patni brings over 25 years of biopharmaceutical experience and a track record of 10 regulatory approvals, which is a positive signal for the company's clinical-stage pipeline execution. This is a routine executive hire for a clinical-stage biotech and does not include any financial data or guidance changes.
Key Facts
- Septerna appointed Rajiv Patni, M.D., as Chief Medical Officer, effective August 24, 2026.
- Dr. Patni has over 25 years of experience and has contributed to 10 regulatory agency approvals or label expansions.
- He most recently served as CEO of Judo Bio and previously as CMO at Global Blood Therapeutics, Portola Pharmaceuticals, and Adamas Pharmaceuticals.
- The filing contains no financial data, guidance, or material business updates.
Financial Impact
No financial impact disclosed in the filing.
Risk Factors
- No financial data or guidance was provided in the filing.
- The appointment does not change the company's near-term cash runway or clinical timelines.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-364210 |
| Document: 0001193125-26-364210-index.html | 0001193125-26-364210 |
| Document: 0001193125-26-364210.txt | 0001193125-26-364210 |
Track record
25 reports on SEPN
7 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +55.96% at T+60 after the Apr 13, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry price pending
- Nov 16, 2026today 144 Neutral 2/10 Entry price pending
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $42.60 Now $42.60 −0.00% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $42.60 Now $42.60 −0.00% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $41.86 Now $42.60 +1.77% settles Nov 19
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $52.34 Now $42.60 +18.61% settles Nov 17
- Nov 4, 202612d ago 8-K Neutral 3/10 Entry $47.88 to $48.56 Now $42.60 −11.03% ▲ +1.42% +2.33% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $47.88 to $48.56 Now $42.60 −11.03% ▲ +1.42% +2.33% vs SPY
- Sep 10, 20269w ago Press Release Neutral 2/10 Entry $38.51 to $38.69 Now $42.60 +10.62% ▲ +0.47% +0.69% vs SPY
- Sep 3, 202610w ago 3 Neutral 2/10 Entry $36.75 to $39.55 Now $42.60 +15.92% ▲ +7.62% +8.83% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers